Abstract: The invention provides certain thiazole-substituted aminopyridine compounds of the Formula (I) (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, Cy, and the subscript t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk).

Abstract: An optical guide member (104) includes an optical guide section having an exit end surface (Rx1) including a side a, and an imaging lens (105) forms, on a front surface of a light emitting section (101), an image of the side a in an image of excitation light (L1) on the exit end surface (Rx1).

Abstract: A photoelectric conversion element includes a superlattice semiconductor layer including barrier sub-layers and quantum sub-layers (quantum dot sub-layers) alternately stacked and also includes a wavelength conversion layer containing a wavelength conversion material converting the wavelength of incident light. The wavelength conversion layer converts incident light into light with a wavelength corresponding to an optical transition from a quantum level of the conduction band of the superlattice semiconductor layer to a continuum level of the conduction band.

Abstract: Methods are provided for controlling the shape of antimony selenide (Sb2Se3) synthesized nanostructures. The method dissolves an antimony (III) salt in a first amount of carboxylic acid, forming an antimony precursor. In one aspect, antimony (III) chloride is dissolved in oleic acid. Separately, selenourea is dissolved in oleylamine, forming a selenium precursor. The antimony precursor is combined with the selenium precursor to form a first solution and cause a reaction. The reaction is quenched with a solvent having a low boiling point. In response to quenching the reaction in the first solution, antimony selenide nanorods are formed, having a length in the range of 150-200 nanometers (nm) and a diameter in the range of 20 to 30 nm. Related methods can be used to create, shorter nanorods, nanocrystals, and hollow nanospheres.

Abstract: Provided is a backlight device that includes: LEDs; a LED substrate; a light guide plate having a light-exiting surface, an opposite surface on an opposite side of the light-exiting surface, and a light-receiving face; a chassis; a frame; a heat dissipating member having a bottom part and a raised part; a pair of fixing members, each having a gripping part that extends along a long-side direction of the raised part and that grips each end in the long-side direction of the raised part in a direction perpendicular to a plate surface of the raised part, and a locking part that extends along the long-side direction of the raised part and that is locked to each of side faces adjacent to the light-receiving face of the light guide plate on a side of the light-receiving face. The pair of fixing members keeps a distance between the LED substrate and the light guide plate constant by fixing a distance between the gripping part and the locking part.

Abstract: The present invention is directed to a novel process for synthesizing 3-(substituted phenoxy)-1-[(5-oxo-4,5-dihydro-1H-1,2,4-triazol-3-yl)methyl])-pyridin-2(1H)-one derivatives. The compounds synthesized by the processes of the invention are HIV reverse transcriptase inhibitors useful for inhibiting reverse transcriptase and HIV replication, and the treatment of human immunodeficiency virus infection in humans.

Abstract: Disclosed herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein each of the substituents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions containing the compound of Formula (I) and use of the compound in the treatment of neurodegenerative diseases or conditions such as Alzheimer's disease.

Abstract: Throughput is improved in a wireless environment in which various types of interference are caused. Included are a reception unit that receives a first reference signal which corresponds to the base station apparatus and a second reference signal which is based on interference information that is configured by the base station apparatus; a channel state information generation unit that generates channel state information based on the first reference signal and the second reference signal; and a transmission unit that transmits the channel state information to the base station apparatus. The channel state information generation unit generates the channel state information considering the second reference signal as an interference signal.

Abstract: A terminal device capable of communicating with a base station device includes a reception unit which performs first measurement based on a first RS and performs second measurement based on a second RS, and a higher layer processing unit which reports a result of the first measurement and a result of the second measurement to the base station device. The result of the first measurement is reported to the base station device in a first state. The result of the first measurement or the result of the second measurement is reported to the base station device in a second state.

Abstract: The present invention is directed to compounds of Formula I pharmaceutical compositions comprising the same, and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS.

Abstract: Degradation in reception performance due to interference is reduced while suppressing control information from increasing. A terminal device receives a first reception signal and a second reception signal, includes a higher layer processing unit that determines NAICS information indicating whether it is indicated in a higher layer that NAICS has to be applied, and a control unit that performs control in such a manner that, in a case where the NAICS is configured in the higher layer, an ACK/NACK of the first reception signal is transmitted and an ACK/NACK of the second reception signal is not transmitted.

Abstract: A field-effect transistor (a GaN-based HFET) includes a gate electrode, a gate electrode pad, a first wiring line connecting one end of the gate electrode and the gate electrode pad, a second wiring line connecting the other end of the gate electrode and the gate electrode pad, and a resistance element that is connected to the first wiring line and is capable of adjusting the impedance of the first wiring line.

Abstract: A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof.

Abstract: There is provided a communication system that performs a service based on ProSe under the management of a communication provider. The communication provider performs a process based on a procedure of an announcement request, a monitoring request or a match report request for discovering a proximity terminal based on the authentication of a server device operated by the communication provider. The communication provider includes means for requesting that the process based on the procedure of the announcement request, the monitoring request or the match report request is stopped based on the policy of the communication provider.

Abstract: In a terminal device that uses a plurality of cells, the plurality of cells are grouped into a cell group for a first base station device and a cell group for a second base station device, and processing for activation/deactivation of the plurality of cells is performed on a cell in the cell group that receive a control element indicating the activation/deactivation, and in a case where the cell group for the second base station is added, a power headroom indicating capacity available for transmit power in the plurality of cells is determined as being triggered, and power headrooms of the plurality of cells that are activated are reported.

Abstract: The invention provides certain pyrazine-2-carboxamide compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein A, B, and X are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk).

Abstract: There is provided a communication system that performs a service based on ProSe under management of a communication operator. A process based on a procedure such as an announcement request, a monitoring request, or match reporting for discovering a proximity terminal is performed based on authentication of a server device operated by the communication operator. The communication operator includes means for requesting that the process based on the procedure such as the announcement request, the monitoring request, or the match reporting is stopped based on a policy of the communication operator.

Abstract: Provided are a communication control method in which selection by a communication terminal of an access network is controlled using a policy for selecting an access network that is transmitted by a server of a home operator and a policy for selecting the access network, which is transmitted by a base station apparatus, and the like. By notifying the communication terminal of a policy for selection of the access network by a server and a policy for selection of the access network by the base station apparatus, a home operator can control selection of the access network by the communication terminal.

Abstract: A mobile station (MS) obtains a parameter, performs transmission of a preamble, and sets a counter incremented based on transmission of the preamble. The MS is able to indicate a random access problem corresponding to one transmission timing cell group in a case where the counter reaches the parameter+1 and the transmission of the preamble is performed on the one transmission timing cell group, where the one transmission timing cell group being one of the plurality of transmission timing cell groups, and the MS is able to not indicate a random access problem corresponding to another transmission timing cell group in a case where the counter reaches the parameter+1 and the transmission of the preamble is performed on the another transmission timing cell group, where the another transmission timing cell group being one of the plurality of transmission timing cell groups.

Abstract: A semiconductor device (100) includes: a first line (8) having a first end portion (8T); a second line (2) being insulated from the first line and having a second end portion (2T); a first electrically-conductive portion (9) provided in the neighborhood of the first and second end portions so as to be spaced apart therefrom; a dielectric layer (20) covering them; and a second electrically-conductive portion (38) on the dielectric layer.